YWYuzhang Wu

Yuzhang Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuzhang Wu has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Jian Chen

    Department of Immunology, Army Medical University (Third Military Medical University), Chongqing, China

    4 shared publications
  • Lulu Wang

    Department of Immunology, Army Medical University (Third Military Medical University)

    4 shared publications
  • Yunpei Zhao

    Department of Pharmacy, Southwest Hospital, Third Military Medical University

    4 shared publications
  • Boshao Deng

    Department of Immunology, Army Medical University (Third Military Medical University)

    3 shared publications
  • Gui-Qing Li

    Department of Immunology, Army Medical University (Third Military Medical University), Chongqing 400038, China

    3 shared publications
  • Guokang Liu

    Department of Immunology, Army Medical University (Third Military Medical University)

    3 shared publications

Latest Publications

  • Open Access

    The complement system in Alzheimer’s disease: mechanisms, biomarkers, and therapeutic implications

    by Guokang Liu, Boshao Deng, Xiao Han, Yunpei Zhao, Shiyu Zeng, Suqin Yu, Lulu Wang, Siyi Wang, Yufei Wu, Linyuan Cai, et al.

    Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder in which synaptic loss is closely associated with cognitive decline. Although the amyloid hypothesis has long dominated AD research, the limited efficacy of amyloid-targeted therapies highlights the need to explore additional pathogenic mechanisms. Increasing evidence indicates that dysregulation of the complement system plays a critical role in AD, linking genetic risk, protein aggregation, neuroinflammation, and neurodegeneration. Under physiological conditions, complement signaling is essential for neural development and synaptic refinement; however, in AD, aberrant activation contributes to excessive synaptic pruning and sustained inflammatory responses. As a result, complement components have attracted attention as potential biomarkers and therapeutic targets, despite limitations in disease specificity. This review summarizes current advances in understanding complement system alterations in AD, discusses their roles in disease pathogenesis, and highlights emerging complement-targeted therapeutic strategies, as well as remaining challenges related to intervention timing, patient stratification, and blood–brain barrier delivery.


  • Open Access

    The novel B-cell epitope peptide vaccine, MAX449, exhibits significant anti-tumor efficacy and enhances the therapeutic effects of PD-1 antibodies on tumors by modulating the activity of PMN-MDSCs

    by Hong Yang, Xiao Han, Boshao Deng, Yunpei Zhao, Jing Zhao, Yufei Wu, Guokang Liu, Shiyu Zeng, Siyi Wang, Zhejuan Shen, et al.

    Rationale: Evidence accumulating across experimental studies and clinical settings supports a central role for the C5a-C5aR signaling axis in promoting tumor progression and immune evasion. Nevertheless, whether a vaccination approach targeting C5a can elicit robust anti-tumor immune responses and suppress tumor growth has not yet been investigated. This research aimed to develop an efficient B-cell peptide epitope vaccine targeting the C5a-C5aR pathway for cancer therapy.


  • Open Access

    C5a/C5aR pathway blocking promoted CuS-mediated cancer therapy effect by inhibiting cuproptosis resistance

    by Hong Yang, Boshao Deng, Xiao Han, Lulu Wang, Jing Zhao, Yunpei Zhao, Zihan Sun, Siyi Wang, Guokang Liu, Yuzhang Wu, et al.

    Background Breast cancer is the most diagnosed malignancy and a leading cause of cancer-related deaths among women globally. Cuproptosis plays a significant role in tumor progression and therapeutic response. Increasing studies suggest that targeting cuproptosis presents a promising strategy for cancer therapy, such as through the development of copper nanoparticles as therapeutic agents. However, resistance to cuproptosis has emerged as a critical hallmark of cancer. Therefore, it is essential to further investigate the mechanisms underlying cuproptosis resistance to enhance its therapy effect. Methods The relationship between breast cancer progression and the C5a/C5aR pathway or cuproptosis was determined by single-cell RNA sequencing analyses, RNA-sequence analyses, bioinformatic analyses, survival analyses and immunohistochemistry. The antitumor effects of CuS nanoparticles and C5a receptor antagonists (C5aRA) were assessed by in vitro and in vivo strategies including cell counting kit-8, colony formation assay, relative reactive oxygen species level assay, western blots, real-time quantitative PCR, immunohistochemistry, immunofluorescence assay, flow cytometry and the xenograft mice models. Complement system activation by CuS nanoparticles was tested by ELISA. Results Our results indicated that activation of the C5a/C5aR pathway contributes to cuproptosis resistance by upregulating ATP7B expression via the Wnt/β-catenin pathway. Consequently, combining CuS nanoparticles with lazer treatment and C5aRA markedly enhanced the antitumor efficacy of CuS nanoparticles by overcoming cuproptosis resistance, leading to a synergistic effect in cancer therapy that included cuproptosis-targeting therapy, immunotherapy, and photothermal therapy. Conclusions This study reports, for the first time, proved C5a/C5aR pathway-mediated cuproptosis resistance in cancer cells, and combining CuS nanoparticles and C5aRA offers a superior and novel therapeutic strategy for cancer.


  • Open Access

    A novel hollow iron nanoparticle system loading PEG-Fe3O4 with C5a receptor antagonist for breast cancer treatment

    by Hong Yang, Guiqing Li, Ji Zhang, Jing Zhao, Yunpei Zhao, Yufei Wu, Zihan Sun, Shuangshuang Song, Ying Zou, Zhihao Zou, et al.

    Breast cancer is the most diagnosed malignancy and major cause of cancer death among women population in the worldwide. Ferroptosis is a recently discovered iron-dependent regulated cell death involved in tumor progression and therapeutic response. Moreover, increasing studies have implied that ferroptosis is a promising approach to eliminating cancer cells like developing iron nanoparticles as a therapeutic agent. However, resistance to ferroptosis is a vital distinctive hallmark of cancer. Therefore, further investigation of the mechanism of ferroptosis resistance to enhance its tumor sensitivity is essential for ferroptosis-target breast cancer therapy. Our results revealed that the activation of C5a/C5aR pathway can drive resistance to ferroptosis and reshaping breast cancer immune microenvironment. Accordingly, loading PEG-Fe3O4 with C5aRA significantly improved the anti-tumor effect of PEG- Fe3O4 by inhibiting ferroptosis resistance and increasing macrophage polarization toward M1 phenotype. Our findings presented a novel cancer therapy strategy that combined cancer cell metal metabolism regulation and immunotherapy. The study also provided support for further evaluation of PEG- Fe3O4@C5aRA as a novel therapeutic strategy for breast cancer in clinical trials.


  • Open Access

    C5aR deficiency attenuates the breast cancer development via the p38/p21 axis

    by Jian Chen, Zi-Han Sun, Li-Ying Chen, Feng Xu, Yun-Pei Zhao, Gui-Qing Li, Ming Tang, You Li, Quan-You Zheng, Shu-Feng Wang, et al.

    Emerging evidence has shown activation of the complement component C5 to C5a in cancer tissues and C5aR expression in breast cancer cells relates to the tumor development and poor prognosis, suggesting the involvement of complement C5a/C5aR pathway in the breast cancer pathogenesis. In this study, we found that as compared to the non-tumoral tissues, both C5aR and MAPK/p38 showed an elevated expression, but p21/p-p21 showed lower expression, in the tumoral tissues of breast cancer patients. Mice deficient in C5aR or mice treated with the C5aR antagonist exhibited attenuation of breast cancer growth and reduction in the p38/p-p38 expression, but increase in p21/p-p21 expression, in the tumor tissues. Pre-treatment of the breast cancer cells with recombinant C5a resulted in reduced p21 expression, and MAPK/p38 inhibitors prevented C5a-induced reduction in p21 expression, suggesting the involvement of the MAPK/p38 signaling pathway in the C5a/C5aR-mediated suppression of p21/p-p21 expression. These results provide evidence that breast cancer development may rely on C5a/C5aR interaction, for which MAPK/p38 pathway participate in down-regulating the p21 expression. Inhibition of C5a/C5aR pathway is expected to be helpful for the treatment of patients with breast cancer.


  • Complement C5a/C5aR pathway potentiates the pathogenesis of gastric cancer by down-regulating p21 expression

    by Jian Chen, Gui-Qing Li, Li Zhang, Ming Tang, Xu Cao, Gui-Lian Xu, Yu-Zhang Wu


  • Open Access

    C5a/C5aR Pathway Is Essential for the Pathogenesis of Murine Viral Fulminant Hepatitis by Way of Potentiating Fgl2/Fibroleukin Expression

    by Gui-Lian Xu, Jian Chen, Fei Yang, Gui-Qing Li, Li-Xin Zheng, Yu-Zhang Wu

    Viral fulminant hepatitis (FH) remains a serious clinical problem with very high mortality. Lacking understanding of FH pathogenesis has in essence hindered efficient clinical treatment. Inferring from a correlation observed between the genetic differences in the complement component 5 (C5) and the susceptibility of mouse strains to murine hepatitis virus strain-3 (MHV-3) infections, we propose that excessive complement activation plays a critical role in the development of FH. We show that MHV-3 infection causes massive complement activation, along with a rapid increase in serum C5a levels and quick development of FH in susceptible strains. Mice deficient in the C5a receptor (C5aR) or the susceptible strains treated with C5aR antagonists (C5aRa) exhibit significant attenuation of the disease, accompanied by a remarkable reduction of hepatic fibrinogen-like protein 2 (Fgl2), a hallmark protein that causes necrosis of infected livers. In accordance, biopsy of FH patients shows a dramatic increase of Fgl2 expression, which correlates with C5aR up-regulation in the liver. In vitro C5a administration accelerates MHV-3-induced Fgl2 secretion by macrophages. Furthermore, inhibiting ERK1/2 and p38 efficiently blocks C5a-mediated Fgl2 production during viral infections. Conclusion : These data provide evidence that mouse susceptibility to MHV-3-induced FH may rely on C5a/C5aR interactions, for which ERK1/2 and p38 pathways participate in up-regulating Fgl2 expression. Inhibition of C5a/C5aR interactions is expected to be beneficial in the clinical treatment of FH patients. (Hepatology 2014;60:114–124)